Form 8-K - Current report:
SEC Accession No. 0001193125-25-204308
Filing Date
2025-09-16
Accepted
2025-09-16 08:00:42
Documents
12
Period of Report
2025-09-11
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d80889d8k.htm   iXBRL 8-K 22031
  Complete submission text file 0001193125-25-204308.txt   134620

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ovid-20250911.xsd EX-101.SCH 2845
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ovid-20250911_lab.xml EX-101.LAB 17992
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ovid-20250911_pre.xml EX-101.PRE 11257
14 EXTRACTED XBRL INSTANCE DOCUMENT d80889d8k_htm.xml XML 3632
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 251315855
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)